Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine shortens the T1 relaxation time of water protons in tissues by binding to plasma proteins and distributing in the extracellular space. This results in increased signal intensity on T1‑weighted MRI sequences, providing clearer contrast between normal and abnormal tissues during the scan.

The dose of Multihance is determined by the prescribing physician based on the specific imaging protocol, the patient’s body weight, and renal function. The prescriber calculates the appropriate volume to achieve optimal contrast enhancement while minimizing potential risks.

Safety of Multihance in pregnancy and lactation has not been established. It should be used only if the potential diagnostic benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Multihance contains gadobenate dimeglumine, which has a higher protein‑binding profile than many conventional gadolinium agents, offering stronger T1 shortening and potentially better lesion detection, especially in liver imaging. However, the choice of agent depends on the clinical indication, patient renal function, and institutional preferences.

Multihance should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside the recommended range.

Multihance is administered intravenously as an injectable solution. The prescribed volume is injected through a peripheral or central line, typically as a rapid bolus followed by a saline flush, according to the imaging protocol defined by the radiology team.

The most serious risks include severe allergic reactions such as anaphylaxis, nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, and rare events like hypotension, cardiac arrest, or seizures. Immediate medical attention is required if any of these reactions occur.

Multihance should be avoided in patients with known hypersensitivity to gadobenate dimeglumine or any component of the formulation, and in those with severe renal dysfunction (e.g., GFR < 30 mL/min/1.73 m²) due to the risk of NSF. Caution is also advised for pregnant or breastfeeding women when alternative imaging methods are available.